In human primary bone tumors of various histological origins, metabolism of testosterone led to the formation of 5o~-reduced metabolites (mainly 5c~-androstane-3a,17[3-diol, and 5a-androstane-3[3-1713-diol), but not 5o~-dihydrotestosterone. Transformation of 5r testosterone to other metabolites in human primary osteosarcomas is assumed to be associated with its inactivation or involvement of metabolites of this androgen in unknown regulatory mechanisms in bone tumors. Therefore, in vitro evaluation of 5~-reductase activity in human primary osteosarcomas and other tumors by 5o~-dihydrotestosterone formation could yield erroneous results.
Key Words: bone tumors; androgens; metabolismPathogenesis of bone tumors is obviously associated with enhanced androgen biosynthesis. On the other hand, these tumors can produce some androgens [1,2,4]. This implies the involvement of androgens in the regulation of some functions in bone tumors and the presence of androgen-metabolizing enzymes in the bone tissues.Metabolism of androgens in various target tissues has long been studied, but the data on bone tissues are contradictory. These tissues were shown to express some enzymes of androgen metabolism [1 1,12].Our recent experiments showed that androgens are metabolized in human primary osteosarcomas containing the main enzymes of androgen metabolism. Activities of 3o~-hydroxysteroid oxidoreductase (3~-HSOR) and 3[3-hydroxysteroid oxidoreductase (313-HSOR) far surpassed those of other enzymes. In spite of relatively high activity of A4steroid:NAD(P)-oxidoreductase (5(z-R) in osteosarcomas, biotransformation of testosterone did not lead to the formation of 5~-dihydrotestosterone (5o~-DHT) in the majority of tumors. However, other 5~-reduced metabolites, 5cz-androstane-3~, -androstane-313,1713-diol (3[3-D) were found in these tumors.Here we compared the formation of 5~-DHT from testosterone in osteosarcoma, chondrosarcoma, and giant cell tumor and benign bone neoplasms.
MATERIALS AND METHODSPatients with osteosarcoma (n=19), chondrosarcoma (n=10), giant cell bone tumor (n=7), and benign bone tumor (n=5) were examined.Testosterone androgens 5~-DHT, 3~-D, 313-D, 5~-androstane-3,17-dione, 4-androstene-3,17-dione (A4) were form Sigma, and other reagents from Merck and Beckman. [ 1,2,6,7-3H]-Testosterone (3H-testosterone, specific activity 80-110 Ci/mmol) and 5~-dihydro-[1,2,6,7-3H]-testosterone (3H-DHT, specific activity 80-105 Ci/mmol, Amersham) were used.Silufol plates (15x15 cm) coated with Silica gel (100 ~t) were used for separation of metabolites and purification of 3H-testosterone and 3H-DHT. Chromatography was performed 3 times in benzene:acetone: ethanol system (9:1:0.5 volume ratio). This procedure allowed us to separate not only the main androgen metabolites, but also 3c~-D and 313-D stereoisomers.